IP Library Granted Patent US 9,642,949
Granted Patent B2
US 9,642,949 · App. 14/212,325 · Granted May 9, 2017

Immobilization of an active agent on a substrate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,642,949
App. No.
14/212,325
Granted
May 9, 2017
Kind
B2
Abstract

The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, depositing a primer compound on a substrate, thereby forming a primed substrate, contacting the primed substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated primed substrate, and contacting the trihydroxyphenyl-treated primed substrate with a solution of an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the primed substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof.

Claims (11)

1. A substrate having an active agent immobilized on a surface thereof, the substrate comprising a layer of a primer compound on the substrate surface, wherein the layer of the primer compound includes a compound including a trihydroxyphenyl group coupled thereto selected from the group consisting of gallic acid, phloroglucinol carboxylic acid, gallamide, 5-methyl-benzene-1,2,3-triol, 3,4,5-trihydroxybenzaldehyde, 2,3,4-trihydroxybenzaldehyde, gallacetophenone, 3,4,5-trihydroxybenzamide, 2,3,4-trihydroxybenzoic acid, 5-hydroxydopamine hydrochloride, methyl gallate, derivatives thereof, salts of the foregoing, and combinations thereof, and wherein the compound comprising the trihydroxyphenyl group includes an active agent coupled thereto.

2. The substrate of claim 1 , wherein the substrate is metal, inorganic oxide, ceramic, semiconductor, or polymeric.

3. The substrate of claim 1 , wherein the trihydroxyphenyl group is selected from the group consisting of a small molecule comprising a trihydroxyphenyl group and a polymer comprising a trihydroxyphenyl group.

4. The substrate of claim 1 , further comprising a linker compound coupled to the trihydroxyphenyl group and/or the primer compound, wherein the linker compound includes an active agent coupled thereto.

5. The substrate of claim 1 , wherein the primer layer on the article has a thickness in a range of about 0.1 nm to about 100 μm.

6. The substrate of claim 1 , wherein the primer is selected from the group consisting of oligosaccharides, polyamines, amino functionalized silanes, and combinations thereof.

7. The substrate of claim 1 , wherein the active agent is selected from the group consisting of antimicrobial agents, antifouling agents, anticoagulants, anti-inflammatory agents, antithrombogenic agents, and combinations of the foregoing.

8. The substrate of claim 1 , wherein the active agent is selected from the group consisting of chitosan, linear polyethylene glycol, looped polyethylene glycol, polyethylene glycol derivatives, fractionated heparin, unfractionated heparin, heparin derivatives, quaternary ammonium polymers, albumin, polyethylenimine, 4-hydroxycoumarin derivatives, and combinations of the foregoing.

9. A medical device comprising the substrate of claim 1 .

10. The medical device of claim 9 , wherein the medical device comprises an extracorporeal blood circuit.

11. The medical device of claim 9 , wherein the medical device comprises tubing, the substrate comprises polysulfone, the primer compound comprises an oligosaccharide, and the active agent comprises heparin.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2025
From: BAXTER HEALTHCARE SA
To: VANTIVE HEALTH GMBH
Reel/Frame 074042/0101 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2025
From: BAXTER INTERNATIONAL INC.
To: VANTIVE US HEALTHCARE LLC
Reel/Frame 074047/0461 →
SECURITY INTEREST Recorded Jan 31, 2025
From: VANTIVE US HEALTHCARE LLC; GAMBRO RENAL PRODUCTS, INC.
To: ARES CAPITAL CORPORATION
Reel/Frame 070076/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2014
From: HAI, TON THAT; GREEN, JOHN-BRUCE DEVAULT; FULGHUM, TIMOTHY MICHAEL
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 032778/0102 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2014
From: MESSERSMITH, PHILLIP BYRON; SILEIKA, TADAS STANISLOVAS
To: NORTHWESTERN UNIVERSITY
Reel/Frame 032778/0249 →